A placebo‐controlled trial of mirtazapine for the management of methamphetamine withdrawal
Open Access
- 29 May 2008
- journal article
- research article
- Published by Wiley in Drug and Alcohol Review
- Vol. 27 (3), 326-333
- https://doi.org/10.1080/09595230801935672
Abstract
Introduction and Aims. As an antidepressant with sedative and anxiolytic properties, mirtazapine may be an appropriate pharmacotherapy for methamphetamine withdrawal. This study sought to examine whether mirtazapine improves retention and alleviates methamphetamine withdrawal symptoms in an out‐patient setting. Design and Methods. An out‐patient double‐blind, randomised placebo‐controlled trial of mirtazapine for the treatment of methamphetamine withdrawal was conducted (15 mg nocte for 2 days, 30 mg nocte for 12 days). Both groups were offered narrative therapy counselling. Measures recorded on days 0, 3, 7, 14 and 35 included: treatment retention, Amphetamine Cessation Symptoms Assessment, the Athens Insomnia Scale, the Brief Symptom Inventory, the Depression–Anxiety–Stress Scale (DASS), Severity of Dependence scale and the Opiate Treatment Index Drug Use subscale. Results. Thirty‐one participants were recruited (18 placebo, 13 mirtazapine) and 52% completed the 2‐week medication phase. No significant differences between the mirtazapine and placebo groups in retention, or any symptom measure were observed, except greater DASS–anxiety and longer sleep duration were measured at baseline among the mirtazapine group. Discussion and Conclusions. Results suggest that mirtazapine does not facilitate retention or recruitment in out‐patient methamphetamine withdrawal treatment, although recruitment may have been insufficient to identify a significant treatment effect. The potential role of narrative therapy for methamphetamine dependent patients deserves further exploration.This publication has 39 references indexed in Scilit:
- Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependenceDrug and Alcohol Dependence, 2006
- Mirtazapine Treatment of Social Phobia in WomenJournal of Clinical Psychopharmacology, 2005
- The nature, time course and severity of methamphetamine withdrawalAddiction, 2005
- Depression and other psychological health problems among methamphetamine dependent patients in treatment: Implications for assessment and treatment outcomeAustralian Psychologist, 2005
- Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for PsychopharmacologyJournal of Psychopharmacology, 2004
- Association of Dopamine Transporter Loss in the Orbitofrontal and Dorsolateral Prefrontal Cortices With Methamphetamine-Related Psychiatric SymptomsAmerican Journal of Psychiatry, 2003
- Psychometric properties of the 42-item and 21-item versions of the Depression Anxiety Stress Scales in clinical groups and a community sample.Psychological Assessment, 1998
- Validation of the amphetamine dependence syndrome and the SAmDQAddiction, 1997
- The structure of negative emotional states: Comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety InventoriesBehaviour Research and Therapy, 1995
- Amphetamine withdrawal and sleep disturbanceDrug and Alcohol Dependence, 1982